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α-Tocopherol succinate Nanostructured Lipid carriers for the Ocular delivery of the
antineoplastic agent
i. Project Summary
Overview: Retinoblastoma (RB) is a rare form of cancer that rapidly develops from the immature
cells of the retina, the light-detecting tissue of the eye. The treatment options of RB has been
limited to enucleation, external beam radiotherapy, episcleral plaque radiotherapy and
cryotherapy. α-Tocopherol succinate (αTS), has been proven to an effective apoptogenic agent. It
can enhance the efficiency of the anticancer agent1. Paclitaxel (Ptx) is a potent chemo agent and is
widely used in the treatment of various types of cancers. However, clinical use of Paclitaxel is
limited by systemic toxicity, rapid clearance and resistance2,3. The formulation of paclitaxel poses
the challenge of incorporation of drug in a Chremophor free and organic solvent free matrix.
Moreover, the blood-retinal barrier also limits the potential of Ptx. αTS and Ptx when combined
together can exert a synergistic effect, thus increasing the efficiency while reducing the required
dose of the anti-cancer agent.
Intellectual Merit: Paclitaxel a taxane compound, originally derived from the bark of Pacific yew
is extensively researched and used in treatment of various types of cancers2. Paclitaxel acts by
binding and inactivating the intracellular proteins necessary for cell survival and functioning, thus
including cell death3,4. αTS is a succinic acid ester form of Vitamin E, a variate more stable than
the α-tocopherol1. The normal cells can hydrolyze the αTS to the original α-tocopherol, while the
cancer cells lack the machinery to convert the ester to the original form, resulting in the cytotoxic
activity of α-TS. Thus, this mechanism can be implemented along with Ptx for anticancer therapy.
The conventional methods of treatments in retinoblastoma consists of systemic delivery of
the chemotherapeutic agents leading to severe side effects and decreased bioavailability5. The
delivery of drugs by the ocular routes can help overcome this challenge along with advantages
such as ease of administration, increased precorneal residence time and enhancement in ocular
bioavailability of drugs6. The NLCs can be pass through the corneal barriers as well as they can
deliver the drug to the posterior section of eye7. The controlled release of Paclitaxel from the NLC
will ensure that therapeutic levels of drugs are maintained at the site of action. This will reduce the
amount of drug required to induce the cytotoxic action. Thus, Paclitaxel and α-Tocopherol
succinate together can show synergistic activity. The FDA approved paclitaxel formulation
constitute paclitaxel in Chremophor EL and Ethanol. Due to the inherent toxicity of Chemophor
and deleterious effects of ethanol on eye8,9, this formulation cannot be used for ocular drug
delivery. Hence, the objective of this study was to formulate paclitaxel delivery system, without
chemophor or any organic solvent.
External Funding Opportunities –
The data from the project will be used by the institution for the following grant application
Sponsor – National Institutes of Health (NIH)
Title - NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI
Omnibus R03 Clinical Trial Optional)
Funding Opportunity Number: PAR-20-052
Funding amount - $50000
Application Due Date - Jan 07, 2023
This funding opportunity will help advance the nano-formulations in cancer treatment and will
also help me have project funded from my data. This opportunity will be a boost to seek a future
position as a scientific researcher.

